Efficacy of Aclidinium Bromide According to Baseline Therapy: Post-Hoc Analysis of ASCENT-COPD Randomized Trial.
- Published in:
- Advances in Therapy, 2021, v. 38, n. 10, p. 5381, doi. 10.1007/s12325-021-01878-5
- By:
- Publication type:
- Article
Works by Daoud, Sami Z.
Results: 7
1
2
An Evaluation of the Pharmacokinetics, Safety, and Tolerability of Aclidinium/Formoterol Fixed-Dose Combination Administered in Chinese Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease.
- Published in:
- Drugs in R&D, 2022, v. 22, n. 1, p. 35, doi. 10.1007/s40268-021-00374-z
- By:
- Publication type:
- Article
3
Long-acting antimuscarinic therapy in patients with chronic obstructive pulmonary disease receiving beta-blockers.
- Published in:
- 2021
- By:
- Publication type:
- journal article
4
Effect of Aclidinium Bromide on Major Cardiovascular Events and Exacerbations in High-Risk Patients With Chronic Obstructive Pulmonary Disease: The ASCENT-COPD Randomized Clinical Trial.
- Published in:
- 2019
- By:
- Publication type:
- journal article
5
The Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide 400 μg Administered by Inhalation as Single and Multiple (Twice Daily) Doses in Healthy Chinese Participants.
- Published in:
- International Journal of COPD, 2023, v. 18, p. 2725, doi. 10.2147/COPD.S434588
- By:
- Publication type:
- Article
6
The Impact of Exacerbation History on the Safety and Efficacy of Aclidinium in Patients with Chronic Obstructive Pulmonary Disease and Increased Cardiovascular Risk: ASCENT-COPD Trial.
- Published in:
- International Journal of COPD, 2021, v. 16, p. 689, doi. 10.2147/COPD.S285068
- By:
- Publication type:
- Article
7
Characteristics of New Users of Aclidinium Bromide, Aclidinium/Formoterol, and Other COPD Medications in the United Kingdom, Denmark, and Germany.
- Published in:
- Clinical Drug Investigation, 2022, v. 42, n. 4, p. 319, doi. 10.1007/s40261-022-01120-2
- By:
- Publication type:
- Article